WO2011053134A3 - Determination of genetic risk for ventricular fibrillation - Google Patents

Determination of genetic risk for ventricular fibrillation Download PDF

Info

Publication number
WO2011053134A3
WO2011053134A3 PCT/NL2010/050715 NL2010050715W WO2011053134A3 WO 2011053134 A3 WO2011053134 A3 WO 2011053134A3 NL 2010050715 W NL2010050715 W NL 2010050715W WO 2011053134 A3 WO2011053134 A3 WO 2011053134A3
Authority
WO
WIPO (PCT)
Prior art keywords
ventricular fibrillation
determination
genetic risk
genetic
predisposing
Prior art date
Application number
PCT/NL2010/050715
Other languages
French (fr)
Other versions
WO2011053134A2 (en
Inventor
Connie Bezzina
Arthur Arnold Maria Wilde
Original Assignee
Academisch Medisch Centrum Bij De Universiteit Van Amsterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Medisch Centrum Bij De Universiteit Van Amsterdam filed Critical Academisch Medisch Centrum Bij De Universiteit Van Amsterdam
Publication of WO2011053134A2 publication Critical patent/WO2011053134A2/en
Publication of WO2011053134A3 publication Critical patent/WO2011053134A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates generally to the fields of medicine and molecular biology, more specifically to the identification of genetic polymorphisms predisposing to ventricular fibrillation.
PCT/NL2010/050715 2009-10-26 2010-10-26 Determination of genetic risk for ventricular fibrillation WO2011053134A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09174074 2009-10-26
EP09174074.6 2009-10-26

Publications (2)

Publication Number Publication Date
WO2011053134A2 WO2011053134A2 (en) 2011-05-05
WO2011053134A3 true WO2011053134A3 (en) 2011-07-28

Family

ID=41467272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2010/050715 WO2011053134A2 (en) 2009-10-26 2010-10-26 Determination of genetic risk for ventricular fibrillation

Country Status (1)

Country Link
WO (1) WO2011053134A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106868126B (en) * 2017-02-20 2020-06-19 深圳美因医学检验实验室 Fluorescent quantitative PCR detection kit and detection method
JP7165100B2 (en) * 2019-04-23 2022-11-02 ジェネシスヘルスケア株式会社 Method for determining risk of atrial and/or ventricular fibrillation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008381A2 (en) * 2000-07-20 2002-01-31 University Of Utah Research Foundation Common polymorphism in scn5a implicated in drug-induced cardiac arrhythmia
WO2004081576A2 (en) * 2003-03-07 2004-09-23 Sequenom, Inc. Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods
JP2007014244A (en) * 2005-07-06 2007-01-25 Japan Health Science Foundation Method for inspecting genetic disposition of intraventricular conduction disturbance or ventricular fibrillation, and reagent therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008381A2 (en) * 2000-07-20 2002-01-31 University Of Utah Research Foundation Common polymorphism in scn5a implicated in drug-induced cardiac arrhythmia
WO2004081576A2 (en) * 2003-03-07 2004-09-23 Sequenom, Inc. Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods
JP2007014244A (en) * 2005-07-06 2007-01-25 Japan Health Science Foundation Method for inspecting genetic disposition of intraventricular conduction disturbance or ventricular fibrillation, and reagent therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE SNP [Online] XP002563263, retrieved from NCBI Database accession no. ss66808656 *
ELMAS ELIF ET AL: "The P-selectin gene polymorphism val168met: A novel risk marker for the occurrence of primary ventricular fibrillation during acute myocardial infarction", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 51, no. 10, Suppl. A, March 2008 (2008-03-01), & 57TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN-COLLEGE-OF-CARDIOLOGY; CHICAGO, IL, USA; MARCH 29 -APRIL 01, 2008, pages A1, XP002563277, ISSN: 0735-1097 *

Also Published As

Publication number Publication date
WO2011053134A2 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
WO2010045345A3 (en) Treatment method
IL250931A0 (en) Detection of genetic or molecular aberrations associated with cancer
WO2009053041A3 (en) Identification of tumor-associated markers for diagnosis and therapy
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
EP2561352A4 (en) Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
WO2013170170A3 (en) Compositions and methods for gene therapy
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
WO2011041584A3 (en) Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
WO2009153775A3 (en) Methods for distinguishing between specific types of lung cancers
WO2011055215A3 (en) Novel benzopyran kinase modulators
WO2009089120A3 (en) Genetic markers of mental illness
WO2009108217A3 (en) Compositions comprising k-ras sirna and methods of use
EP2569014A4 (en) Treatment methods
WO2009030884A3 (en) Mannosylated butyrophilin tumour markers
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
WO2009039189A3 (en) Compositions comprising stat3 sirna and methods of use thereof
WO2009158374A3 (en) Inhibitors of akt activity
WO2011153431A3 (en) Peripheral blood sparc antibodies and uses thereof
WO2012061502A3 (en) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer
WO2011130426A3 (en) Compositions and methods for treatment of melanoma
WO2011113065A3 (en) Pegylated polyplexes for polynucleotide delivery
WO2013052006A8 (en) Parp-1 inhibitors
WO2011053134A3 (en) Determination of genetic risk for ventricular fibrillation
WO2009143371A3 (en) COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10770642

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10770642

Country of ref document: EP

Kind code of ref document: A2